Delivery Order SPE2DR25D1017-SPE2DR26F8YQL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $13,647.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on May 27, 2025, with a completion date of May 28, 2025. This competitive award, placed under a firm fixed-price contract, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens totaling $8,026.30 on September 25, 2025, with completion expected by September 26, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply arrangement with the federal government. The product will be delivered to AmerisourceBergen's distribution facility in...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. The contract, which is a child order under a larger vehicle, carries an ultimate completion date of August 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,138.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $5,621.91 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with an ultimate completion date of September 17, 2025. This firm fixed price contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,768.60 to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pens on October 28, 2025, with completion targeted for October 29, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The product will be delivered...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,675.26 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F8YQLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,022.29 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on October 28, 2025, with completion scheduled for October 29, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a small-value pharmaceutical procurement for federal medical supply needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. The prime indefinite delivery contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. Zepbound, a GLP-1 receptor agonist indicated for weight management, represents one of the specialized medications within the extensive therapeutic portfolio the company maintains to serve federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 10/28/25 |